SLC18A2
Basic information
Region (hg38): 10:117241093-117279430
Previous symbols: [ "VMAT2" ]
Links
Phenotypes
GenCC
Source: 
- schizophrenia (No Known Disease Relationship), mode of inheritance: Unknown
- brain dopamine-serotonin vesicular transport disease (Supportive), mode of inheritance: AR
- parkinsonism-dystonia, infantile, 2 (Moderate), mode of inheritance: AR
- parkinsonism-dystonia, infantile, 2 (Strong), mode of inheritance: AR
- brain dopamine-serotonin vesicular transport disease (Strong), mode of inheritance: AR
Clinical Genomic Database
Source: 
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References | 
|---|---|---|---|---|---|
| Parkinsonism-dystonia, infantile, 2 | AR | Neurologic | The condition can manifest with neurologic manifestations such as movement disorders and autonomic dysfunctiontreatment, and medical management with a dopamine receptor agonist has been described as resulting in marked clinical improvement | Neurologic | 23363473 | 
ClinVar
This is a list of variants' phenotypes submitted to 
- not_provided (157 variants)
- Inborn_genetic_diseases (48 variants)
- Brain_dopamine-serotonin_vesicular_transport_disease (12 variants)
- SLC18A2-related_disorder (4 variants)
- not_specified (2 variants)
- Abnormal_dense_granule_content (1 variants)
- Abnormal_dense_granules (1 variants)
- Abnormal_brain_morphology (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC18A2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000003054.6. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum | 
|---|---|---|---|---|---|---|
| synonymous | 57 | 58 | ||||
| missense | 82 | 92 | ||||
| nonsense | 2 | |||||
| start loss | 0 | |||||
| frameshift | 7 | |||||
| splice donor/acceptor (+/-2bp) | 2 | |||||
| Total | 6 | 8 | 84 | 59 | 4 | 
Highest pathogenic variant AF is 0.00003779233
GnomAD
Source: 
| Gene | Type | Bio Type | Transcript | Coding Exons | Length | 
|---|---|---|---|---|---|
| SLC18A2 | protein_coding | protein_coding | ENST00000298472 | 15 | 38338 | 
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p | 
|---|---|---|---|---|---|---|
| 0.0755 | 0.924 | 125704 | 0 | 44 | 125748 | 0.000175 | 
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 1.25 | 240 | 301 | 0.797 | 0.0000164 | 3353 | 
| Missense in Polyphen | 35 | 62.569 | 0.55938 | 653 | ||
| Synonymous | -0.0253 | 122 | 122 | 1.00 | 0.00000804 | 1023 | 
| Loss of Function | 3.42 | 7 | 25.7 | 0.272 | 0.00000124 | 297 | 
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p | 
|---|---|---|
| African & African-American | 0.000347 | 0.000347 | 
| Ashkenazi Jewish | 0.0000992 | 0.0000992 | 
| East Asian | 0.0000544 | 0.0000544 | 
| Finnish | 0.000279 | 0.000277 | 
| European (Non-Finnish) | 0.000134 | 0.000132 | 
| Middle Eastern | 0.0000544 | 0.0000544 | 
| South Asian | 0.000229 | 0.000229 | 
| Other | 0.000326 | 0.000326 | 
dbNSFP
Source: 
- Function
- FUNCTION: Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.;
- Pathway
- Synaptic vesicle cycle - Homo sapiens (human);Serotonergic synapse - Homo sapiens (human);Dopaminergic synapse - Homo sapiens (human);Amphetamine addiction - Homo sapiens (human);Parkinson,s disease - Homo sapiens (human);Alcoholism - Homo sapiens (human);Cocaine addiction - Homo sapiens (human);Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics;Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics;Sympathetic Nerve Pathway (Neuroeffector Junction);Nicotine Activity on Dopaminergic Neurons;Synaptic Vesicle Pathway;Dopaminergic Neurogenesis;Amine compound SLC transporters;Tyrosine metabolism;Transport of bile salts and organic acids, metal ions and amine compounds;SLC-mediated transmembrane transport;Transport of small molecules;Neuronal System;Histidine metabolism;Tryptophan metabolism;Na+/Cl- dependent neurotransmitter transporters;Dopamine Neurotransmitter Release Cycle;Neurotransmitter release cycle;Transmission across Chemical Synapses;Serotonin Neurotransmitter Release Cycle;Norepinephrine Neurotransmitter Release Cycle (Consensus) 
Recessive Scores
- pRec
- 0.214
Intolerance Scores
- loftool
- 0.354
- rvis_EVS
- -0.71
- rvis_percentile_EVS
- 14.4
Haploinsufficiency Scores
- pHI
- 0.358
- hipred
- Y
- hipred_score
- 0.830
- ghis
- 0.456
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.194
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium | 
| Primary Immunodeficiency | Medium | Medium | Medium | 
| Cancer | Medium | Medium | Medium | 
Mouse Genome Informatics
- Gene name
- Slc18a2
- Phenotype
- taste/olfaction phenotype; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype;
Zebrafish Information Network
- Gene name
- slc18a2
- Affected structure
- brain
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- response to amphetamine;neurotransmitter transport;chemical synaptic transmission;neurotransmitter secretion;locomotory behavior;post-embryonic development;aminergic neurotransmitter loading into synaptic vesicle;monoamine transport;dopamine transport;sequestering of neurotransmitter;serotonin uptake;transmembrane transport;neurotransmitter loading into synaptic vesicle;negative regulation of reactive oxygen species biosynthetic process
- Cellular component
- plasma membrane;integral component of plasma membrane;synaptic vesicle;membrane;synaptic vesicle membrane;terminal bouton;clathrin-sculpted monoamine transport vesicle membrane;dopaminergic synapse
- Molecular function
- serotonin:sodium symporter activity;monoamine transmembrane transporter activity